PDE3 Inhibition in Dilated Cardiomyopathy: Reasons to Reconsider

Journal of Cardiac Failure

Volumn 9, Issue 6, 2003, Pages 475-480

  Movsesian, Matthew A ^a,b  

^a University of Utah ^*

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Heart failure; Phosphodiesterase inhibitors; Protein phosphorylation; adrenergic receptor antagonists

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE III;

CONGESTIVE CARDIOMYOPATHY; ENZYME INHIBITION; HEART MUSCLE; INOTROPISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0346334593     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(03)00135-0     Document Type: Article

References (45)

1. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999;63:1-38.
2. Shakur Y, Holst LS, Landstrom TR, Movsesian MA, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase PDE3 gene family. Prog Nucleic Acid Res Mol Biol 2000;66:241-77.
3. Movsesian MA. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cAMP. J Am Coll Cardiol 1999;34:318-24.
4. Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 1998;78:921-47.
5. 2+ pump of the sarcoplasmic reticulum. Nature 1989;342:90-2.
6. 2+-activated protease. J Biol Chem 1984;259:8550-7.
7. Takasago T, Imagawa T, Shigekawa M. Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem (Tokyo). 1989;106:872-7.
8. Sculptoreanu A, Rotman E, Takahashi M, Scheuer T, Catterall WA. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 1993;90:10135-9.
9. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA. Hemodynamic assessment of amrinone. N Engl J Med 1978:299:1373-7.
10. Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Engl J Med 1983;309:748-56.
11. Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, Le Jemtel TH. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983;2:327-31.
12. Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP. The acute hemodynamic effects of a new agent. MDL 17.043, in the treatment of congestive heart failure. Circulation 1983;67:823-8.
13. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985;75:643-9.
14. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
15. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993;329:149-55.
16. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-6.
17. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990;82:774-80.
18. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 1994;46:191-6.
19. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
20. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomised Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
21. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
22. Hjalmarson A, Goldstein S, Fagerberg B, Wedel F, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. J Am Med Assoc 2000;283:1295-302.
23. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-858.
24. Goldstein S, Fagerberg B, Hjalmarson A, Kjekshus J, Waagstein F, Wedel H, et al. The MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38:932-8.
25. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and eficcacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999;31:924-31.
26. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised placebo-controlled trail of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-380.
27. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-40.
28. Kumar A, Choudhary G, Antonio C, Just V, Jain A, Heaney L, Papp MA. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001;142:512-5.
29. Hauptman PJ, Woods D, Prirzker MR. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol 2002;25:247-9.
30. Yoshikawa T, Baba A, Suzuki M, Yokozuka H, Okada Y, Nagami K, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 2000;85:1495-7.
31. 2+ channel pathways. J Clin Invest 1999;103:1089-97.
32. 2+ channels: preferential coupling of the beta1 versus beta2 receptor subtype and evidence for PKA-independent activation of the channel. Cell Signal 1999;11:337-42.
33. Yarbrough TL, Lu T, Lee HC, Shibata EF. Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. Circ Res 2002;90:443-9.
34. Schafer M, Frischkopf K, Taimor G, Piper HM, Schluter KD. Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol 2000;279:C495-503.
35. 1. J Biol Chem 1980;255:5113-9.
36. 2+ current in single rat ventricular cells. Circ Res 1993;73:286-300.
37. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 1994;269:19151-6.
38. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 2000;275:41447-57.
39. Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen Y, Lakatta EG, et al. G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling. J Biol Chem 1999;274:22048-52.
40. 2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci 1996;93:295-9.
41. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002;295:1711-5.
42. Rapundalo ST, Solaro RJ, Kranias EG. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989;64:104-11.
43. Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, et al. Identification of a novel isoform of PDE3A cyclic nucleotide phosphodiesterase in vascular smooth muscle myocytes. Biochem J 2001;353:41-50.
44. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 2002;277:38072-8.
45. Liu H, Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 1998;125:1501-10.